Share on StockTwits

Oncomed Pharmaceuticals (NASDAQ:OMED) EVP John A. Lewicki sold 2,191 shares of the company’s stock on the open market in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $20.01, for a total value of $43,841.91. Following the transaction, the executive vice president now directly owns 20,602 shares of the company’s stock, valued at approximately $412,246. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

A number of analysts have recently weighed in on OMED shares. Analysts at BMO Capital Markets reiterated a “hold” rating on shares of Oncomed Pharmaceuticals in a research note on Thursday, August 28th. Separately, analysts at Zacks downgraded shares of Oncomed Pharmaceuticals from a “neutral” rating to an “underperform” rating in a research note on Tuesday, August 12th. They now have a $15.00 price target on the stock. Finally, analysts at Mizuho reiterated a “buy” rating on shares of Oncomed Pharmaceuticals in a research note on Friday, June 13th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and one has given a buy rating to the company. Oncomed Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $37.00.

Oncomed Pharmaceuticals (NASDAQ:OMED) traded down 3.75% on Wednesday, hitting $18.72. The stock had a trading volume of 308,700 shares. Oncomed Pharmaceuticals has a one year low of $12.07 and a one year high of $42.34. The stock’s 50-day moving average is $20.55 and its 200-day moving average is $25.62. The company’s market cap is $557.1 million.

Oncomed Pharmaceuticals (NASDAQ:OMED) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by $0.50. The company had revenue of $6.00 million for the quarter, compared to the consensus estimate of $21.28 million. On average, analysts predict that Oncomed Pharmaceuticals will post $-1.35 earnings per share for the current fiscal year.

OncoMed Pharmaceuticals, Inc (NASDAQ:OMED) is a clinical development-stage biopharmaceutical company.

Receive News & Ratings for Oncomed Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncomed Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.